Sonelokimab Hits All Endpoints in Phase 3 Psoriatic Arthritis Trial, MoonLake Eyes Multi-Billion Dollar Market
MLTX has more than doubled off its 52-week low of $5.95.
Summary
MoonLake's sonelokimab met all primary and secondary endpoints in the Phase 3 IZAR-1 trial for psoriatic arthritis, with 42.1% of patients achieving ACR50 and strong results across skin, joint, and quality-of-life measures. The safety profile remains clean, with no new signals. This de-risks a second major indication beyond hidradenitis suppurativa and opens a multi-billion dollar market. The company ended Q2 with $537M in cash, extending runway to mid-2028, plus access to $400M in non-dilutive debt. Full 52-week data is expected in H1 2027, and the IZAR-2 trial in TNF-refractory patients completes enrollment in Q3 2026.
At the time of this announcement, MLTX was trading at $18.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $5.95 to $62.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.